Codiak BioSciences Stock

codiakbio.comHealthcareFounded: 2015Funding to Date: $168.37MM

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register for Details

For more details on financing and valuation for Codiak BioSciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Codiak BioSciences.

Register Today

Team

Management Team

Douglas E. Williams, Ph.D.
President, Chief Executive Officer & Board Member
Linda C. Bain
Chief Financial Officer
Richard Brudnick
Chief Business Officer & Head of Strategy
Andrea Difabio
Chief Legal Officer

Board Members

Theo Melas-Kyriazi
Jonathan Poole
Eric S. Lander, Ph.D.
Karen Bernstein, Ph.D.
Steven Gillis, Ph.D.
Charles L. Cooney, Ph.D.
Briggs W. Morrison, M.D.
Douglas E. Williams, Ph.D.

Other companies like Codiak BioSciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$885.01MM
Sector
 
 

News

Jazz Pharmaceuticals will use Codiak BioSciences’ engEx™ precision engineering platform to research, develop and commercialize exosome therapeutics for cancer through a collaboration that could generate more than $1 billion for Codiak,